Nxera Pharma.
company in Tokyo, Japan
- Reports this week
- 0
- Active events
- 0
- Connections
- 18
What's happening
Earlier this month
One to three months ago
-
Nxera Pharma has acquired rights to NBI-’567 through Neurocrine Biosciences, with the goal of improving patient outcomes in Japan.Some support2 reports
-
Nxera Pharma is developing and selling biopharmaceutical products in markets including the US, UK, Japan, Switzerland, and Bermuda.Some support1 report
-
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.Some support1 report
Gone quiet
No new reports in 90+ days-
AbbVie and Nxera Pharma announced a collaboration to discover novel medicines.Some support1 report
-
FDA clearance enabled clinical development for Nxera Pharma, which operates in key locations including Cambridge, Basel, and Seoul.Speculative1 report
-
Eli Lilly and Company, Novo Nordisk, and Nxera Pharma are noted as key players in the alcohol use disorder market.Speculative1 report
-
Nxera Pharma collaborates with Centessa Pharmaceuticals to develop a novel orexin receptor 2 agonist, resulting in milestone payments.Some support1 report
-
Nxera Pharma operates in key locations including Basel, Seoul, and Osaka.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Nxera Pharma this week
News at the entities that move Nxera Pharma most-
Eli Lilly and Company StructuralExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Moves Nxera Pharma
-
AbbVie OperationalAbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Moves Nxera Pharma
-
Switzerland Shared contextECB has established swap line arrangements with central banks, with the ECB President leading central bank operations.Moves Nxera Pharma
-
Bermuda Shared contextEl Niño patterns are affecting regional weather, specifically impacting storm development near Bermuda.Moves Nxera Pharma
-
Osaka Shared contextPawn shops are prevalent in Osaka, Japan, reflecting broader economic trends affecting consumer behavior.Moves Nxera Pharma
-
Basel Shared contextBasilea Pharmaceutica is headquartered in Basel, Switzerland.Moves Nxera Pharma
Connections
The 10 strongest of 18, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Eli Lilly and Company Structural
A development partnership exists where Eli Lilly's subsidiary provides milestone payments to Nxera Pharma.
-
Neurocrine Biosciences Operational
The companies are engaged in a collaborative partnership to advance the development of the asset NBI-1117567, which originated from a rights acquisition by Nxera from Neurocrine.
-
AbbVie Operational
AbbVie and Nxera Pharma are engaged in a formal collaboration to discover novel medicines, including potential milestone payments.
-
ADC Therapeutics Operational
The companies are actively competing in the market, as evidenced by direct comparisons of their financial and market performance.
-
Osaka Shared context
Nxera Pharma operates within the key locations of Osaka as part of its global footprint.
-
Switzerland Shared context
Nxera Pharma develops and sells biopharmaceutical products within Switzerland.
-
Basel Shared context
Nxera Pharma operates in Basel, utilizing it as a key location for its business activities.
-
Bermuda Shared context
Nxera Pharma operates and sells biopharmaceutical products within the jurisdiction of Bermuda.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
1 eventJuly 2026
1 eventShow 1 earlier month
June 2026
6 events- A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
- AbbVie and Nxera Pharma announced a collaboration to discover novel medicines.
- FDA clearance enabled clinical development for Nxera Pharma, which operates in key locations including Cambridge, Basel, and Seoul.
- Eli Lilly and Company, Novo Nordisk, and Nxera Pharma are noted as key players in the alcohol use disorder market.
- Nxera Pharma collaborates with Centessa Pharmaceuticals to develop a novel orexin receptor 2 agonist, resulting in milestone payments.
- Nxera Pharma operates in key locations including Basel, Seoul, and Osaka.